Lectenz Bio, Inc.
Athens, GA Doing business as Lectenz Bio
- UEI
- JTGCK219C6F4
- CAGE
- 4XHN3
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 111 Riverbend Rd, Athens, GA 30602, USA
- Website
- lectenz.com
- Founded
- 2007
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Innovative glycan-specific reagents to accelerate the detection of disease biomarkers - project summary glycans have… | National Institute of General Medical Sciences | $1,358,479 | |
| A new approach to monitoring glycosylation during glycoprotein production - project summary during the production of… | National Institute of General Medical Sciences | $3,030,827 | |
| Engineered pan-specific reagents for n-glycan detection and enrichment - project summary glycans play crucial roles in… | Aggregate Financial Assistance Data | $4,319,836 | |
| Novel reagents for monitoring sulfation patterns in heparin and heparan sulfate | National Institute of General Medical Sciences | $893,381 | |
| Development of a suite of high-specificity fucose binding reagents | National Institute of General Medical Sciences | $900,000 |
About Lectenz Bio, Inc.
Lectenz Bio, Inc., registered in SAM.gov since December 2007, is a for-profit corporate entity located in Athens, Georgia, specializing in biotechnology research and development focused on glycan-specific reagents and advanced analytical technologies. The company develops innovative tools and techniques for detecting and analyzing glycans, which are complex carbohydrate structures critical in understanding biological processes and disease markers. Their core technological approach involves engineering glycan-processing enzymes and glycan-binding proteins into high-affinity, specialized reagents with adaptable properties.
The company has secured multiple federal grants from prominent agencies including the National Institute of General Medical Sciences (NIGMS) and the Office of the Director, primarily through Project Grant awards in the Biomedical Research and Research Training program (CFDA 93.859). Their recent grant-funded projects have concentrated on developing advanced glycosylation monitoring technologies, such as the GlycoSense™ platform for tracking protein glycosylation during therapeutic biologics production and engineered reagents for detecting specific glycan structures. Specifically, Lectenz Bio has been working on creating pan-specific N-glycan binding reagents, developing high-affinity "Lectenz" reagents for cancer biomarker detection, and creating innovative flow cytometry-based methods for monitoring glycosylation patterns. These projects aim to provide researchers and pharmaceutical developers with more precise, efficient tools for glycan analysis, with potential applications in disease detection, biomarker research, and therapeutic production quality control.
Quick answers
What is Lectenz Bio, Inc.'s UEI?
Lectenz Bio, Inc.'s Unique Entity ID (UEI) in SAM.gov is JTGCK219C6F4.
What is Lectenz Bio, Inc.'s CAGE code?
Lectenz Bio, Inc.'s CAGE code is 4XHN3.
What is Lectenz Bio, Inc.'s primary NAICS code?
Lectenz Bio, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Lectenz Bio, Inc. located?
Lectenz Bio, Inc.'s physical address in SAM.gov is 111 Riverbend Rd, Athens, GA 30602, USA.
Is Lectenz Bio, Inc. registered in SAM.gov?
Yes. Lectenz Bio, Inc.'s SAM.gov registration is active through September 15, 2027.
What is Lectenz Bio, Inc.'s most recent federal award?
Lectenz Bio, Inc.'s most recent federal grant award is Innovative glycan-specific reagents to accelerate the detection of disease biomarkers - project summary glycans have… (R44GM159548), from National Institute of General Medical Sciences, on July 18, 2025.
On GovTribe
See Lectenz Bio, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors